582 related articles for article (PubMed ID: 2005879)
1. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
3. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships.
Connor K; Ramamoorthy K; Moore M; Mustain M; Chen I; Safe S; Zacharewski T; Gillesby B; Joyeux A; Balaguer P
Toxicol Appl Pharmacol; 1997 Jul; 145(1):111-23. PubMed ID: 9221830
[TBL] [Abstract][Full Text] [Related]
4. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure.
Jordan VC; Lieberman ME
Mol Pharmacol; 1984 Sep; 26(2):279-85. PubMed ID: 6541293
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
Jordan VC; Lieberman ME; Cormier E; Koch R; Bagley JR; Ruenitz PC
Mol Pharmacol; 1984 Sep; 26(2):272-8. PubMed ID: 6482874
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogenic effects of Z-1, 1-dichloro-2,3 diphenyl-2-(4-methoxyphenyl)cyclopropane(5a) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Anticancer Res; 1992; 12(3):585-90. PubMed ID: 1622114
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
9. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
11. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.
Murphy CS; Langan-Fahey SM; McCague R; Jordan VC
Mol Pharmacol; 1990 Nov; 38(5):737-43. PubMed ID: 2233701
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
Coezy E; Borgna JL; Rochefort H
Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
[TBL] [Abstract][Full Text] [Related]
15. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
Kraft KS; Ruenitz PC; Bartlett MG
J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
17. Basic guide to the mechanisms of antiestrogen action.
MacGregor JI; Jordan VC
Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
[TBL] [Abstract][Full Text] [Related]
18. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
Nguyen A; Top S; Pigeon P; Vessières A; Hillard EA; Plamont MA; Huché M; Rigamonti C; Jaouen G
Chemistry; 2009; 15(3):684-96. PubMed ID: 19053086
[TBL] [Abstract][Full Text] [Related]
20. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
